This site is intended for health professionals only
Wednesday 19 December 2018
Share |

Topic: Oncology

November 29, 2018
First child cancer patients treated with new CAR-T therapy in UK

Children with cancer at Great Ormond Street Hospital in London are this week starting a new therapy treatment tailored to target patients’ specific cancer cells.
 
The CAR-T treatment involves collecting and using a patient’s own immune cells to fight the cancer over a number of weeks. 
 
Royal Manchester Children’s Hospital is also offering the immunotherapy treatment, and Newcastle upon Tyne Hospitals NHS Foundation Trust will join next month.
 

November 29, 2018
First child cancer patients treated with new CAR-T therapy in UK

Children with cancer at Great Ormond Street Hospital in London are this week starting a new therapy treatment tailored to target patients’ specific cancer cells.
 
The CAR-T treatment involves collecting and using a patient’s own immune cells to fight the cancer over a number of weeks. 
 
Royal Manchester Children’s Hospital is also offering the immunotherapy treatment, and Newcastle upon Tyne Hospitals NHS Foundation Trust will join next month.
 

November 29, 2018
In the EU, regorafenib is indicated for treatment of adult patients with advanced unresectable hepatocellular carcinoma who have been previously treated with sorafenib
Bayer has announced that the National Institute for Health and Care Excellence (NICE) has recommended Stivarga® (regorafenib) as an option for treating advanced unresectable hepatocellular carcinoma (HCC) in adults who have had Nexavar® (sorafenib) only if patientshave Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.1
 
November 28, 2018
Data from the ALTA trial showed sustained systemic and intracranial efficacy results and a manageable safety profile, leading to the longest progression-free survival and overall survival reported in this setting

Takeda has announced that the European Commission (EC) granted marketing authorisation for Alunbrig (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

 

The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on 20 September, 2018. 

 

November 7, 2018
Olarpip could provide effective treatment for brain tumours, charity reveals

An ovarian cancer drug could be an effective treatment for a difficult-to-treat type of brain tumour, research by a cancer charity has revealed.
 
Olaparib could leak through the blood brain barrier to treat glioblastoma – a condition which many other drugs have failed to treat – according to a study presented at the National Cancer Research Institute’s (NCRI) Cancer Conference in Liverpool on Monday (5 November).
 

November 7, 2018
Olarpip could provide effective treatment for brain tumours, charity reveals

An ovarian cancer drug could be an effective treatment for a difficult-to-treat type of brain tumour, research by a cancer charity has revealed.
 
Olaparib could leak through the blood brain barrier to treat glioblastoma – a condition which many other drugs have failed to treat – according to a study presented at the National Cancer Research Institute’s (NCRI) Cancer Conference in Liverpool on Monday (5 November).
 

October 31, 2018
Scientists discover source for counteracting drug resistance in tumour cells

Researchers have discovered a way of re-sensitising tumour cells that are resistant to cancer drugs.
 
The study, conducted by biologists at the University of California in San Diego, found that a human gene known as Schlafen 11 controls the sensitivity of tumour cells to DNA-damaging agents, which make up most of the widely used cancer drugs.
 

October 31, 2018
Scientists discover source for counteracting drug resistance in tumour cells

Researchers have discovered a way of re-sensitising tumour cells that are resistant to cancer drugs.
 
The study, conducted by biologists at the University of California in San Diego, found that a human gene known as Schlafen 11 controls the sensitivity of tumour cells to DNA-damaging agents, which make up most of the widely used cancer drugs.
 

September 21, 2018
European Commission approves BRAFTOVI and MEKTOVI to treat advanced BRAF-mutant melanoma

The European Commission (EC) had approved the use of BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) to treat adults with advanced BRAF-mutant melanoma.
 
The EC’s decision is based on results from the Phase 3 COLUMBUS trial, which demonstrated 14.9 months median progression-free survival and 33.6 months median overall survival with the combination therapyversus vemurafenib monotherapy with 7.3 and 16.9 months, respectively.
 

September 21, 2018
European Commission approves BRAFTOVI and MEKTOVI to treat advanced BRAF-mutant melanoma

The European Commission (EC) had approved the use of BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) to treat adults with advanced BRAF-mutant melanoma.
 
The EC’s decision is based on results from the Phase 3 COLUMBUS trial, which demonstrated 14.9 months median progression-free survival and 33.6 months median overall survival with the combination therapyversus vemurafenib monotherapy with 7.3 and 16.9 months, respectively.
 

August 30, 2018
The European Commission has approved Vyxeos 44 mg/100mg powder for concentrate for solution for infusion for the treatment of adults with newly-diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes, manufacturer Jazz Pharmaceuticals has announced.

The European Commission has approved Vyxeos 44 mg/100mg powder for concentrate for solution for infusion for the treatment of adults with newly-diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes, manufacturer Jazz Pharmaceuticals has announced.
 
Vyxeos is an advanced liposomal formulation that delivers a synergistic molar ration of daunorubicin and cytarabine, Jazz Pharmaceuticals said.
 
The EC approval extends to all European member states as well as Iceland, Norway sand Liechtenstein.

August 30, 2018
The European Commission has approved Vyxeos 44 mg/100mg powder for concentrate for solution for infusion for the treatment of adults with newly-diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes, manufacturer Jazz Pharmaceuticals has announced.

The European Commission has approved Vyxeos 44 mg/100mg powder for concentrate for solution for infusion for the treatment of adults with newly-diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes, manufacturer Jazz Pharmaceuticals has announced.
 
Vyxeos is an advanced liposomal formulation that delivers a synergistic molar ration of daunorubicin and cytarabine, Jazz Pharmaceuticals said.
 
The EC approval extends to all European member states as well as Iceland, Norway sand Liechtenstein.

August 30, 2018
Novartis UK Oncology statement on Novartis receiving European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)

Novartis UK Oncology statement on Novartis receiving European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)
 
"Today’s (27 August) approval by the European Commission of Kymriah® (tisagenlecleucel), the only CAR-T therapy licensed in two different types of blood cancers, moves us one step closer to providing this revolutionary therapy to appropriate patients in the UK. 
 
 
 

July 26, 2018
Steve Wiliams explains why he loves working in the field of cancer care

Working with cancer patients can be tough at times as despite all the effective new treatments, many patients still have incurable diseases. But being an oncology pharmacist is an amazing job and I would not swap it for anything else. 
 

July 26, 2018
Steve Wiliams explains why he loves working in the field of cancer care

Working with cancer patients can be tough at times as despite all the effective new treatments, many patients still have incurable diseases. But being an oncology pharmacist is an amazing job and I would not swap it for anything else. 
 

July 23, 2018
The introduction of dose banding and the recent publication of product specifications by NHS England have set the ball in motion for the introduction of licensed standardised chemotherapy doses, the benefits of which are discussed here
Chemotherapy is the single biggest service area-spend within NHS England specialised commissioning. In 2016/17, NHS England spent approximately £1.7 billion on the routine commissioning of chemotherapy, with drug costs accounting for the largest proportion (80%).1
 
July 2, 2018
The CHMP has given a positive opinion recommending Novartis’s Kymriah (tisagenlecleucel) to treat two aggressive blood cancers.

The Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending Novartis’s Kymriah (tisagenlecleucel) to treat two aggressive blood cancers.
 
The CHMP, which is part of the European Medicines Agency (EMA), gave a positive opinion on using tisagenlecleucel to treat B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-stem cell transplant or in second or later relapse in patients up to 25 years of age.
 

June 28, 2018
First patient with metastatic breast cancer receives treatment to look at anti-tumour effect and tolerability using new drug response predictor

A drug trial on a patient with metastatic breast cancer selected by a new drug response predictor has been launched.
 

June 21, 2018
Targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors

A targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors, researchers have found.
 
EZH2 is elevated in immune T cells in patients after treatment with ipilimumab, a team at the University of Texas MD Anderson Cancer Center showed. The drug unleashes an immune response by blocking the activity of CTLA-4 on T cells – white blood cells that serve as the ‘targeted warriors’ of the adaptive immune system.
 

June 20, 2018
Manufacturer Amgen has received approval from the European Commission (EC) to include overall survival (OS) data on the labels of the drug BLINCYTO (blinatumomab), it has announced.

Manufacturer Amgen has received approval from the European Commission (EC) to include overall survival (OS) data on the labels of the drug BLINCYTO (blinatumomab), it has announced.
 
The EC granted the company a full marketing authorisation for the drug based on the overall survival date from the Phase 3 TOWER study in adult patients with Philadelphia chromosome-negative (PH-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
 

June 14, 2018
International team of researchers have developed new DNA test to identify men at greatest risk of prostate cancer

A saliva based DNA test to identify men who are at the highest risk of developing prostate cancer is to start early trials.
 
An international team of researchers led by scientists at The Institute of Cancer Research (ICR), London, have developed the new DNA test to unearth new genetic variants that were particularly hard to find.
 

June 14, 2018
Cancer fighting effects of aspirin revealed in bowel tumour study

Taking aspirin could help to prevent bowel cancer, researchers have suggested.
 
Regular use of aspirin is known to reduce the risk of developing colon cancer but the drug’s tumour fighting properties have not been well understood. Researchers at theUniversity of Edinburgh have found that the painkiller blocks a key process linked to tumour formation, shedding light on how taking aspirin can help to stave off bowel cancer.
 

June 12, 2018
A first of its kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer (NSCLC), under a collaboration agreement between Cancer Research UK and Asterias Biotherapeutics Inc.

A first of its kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer (NSCLC), under a collaboration agreement between Cancer Research UK and Asterias Biotherapeutics Inc.

 

June 12, 2018
A first of its kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer (NSCLC), under a collaboration agreement between Cancer Research UK and Asterias Biotherapeutics Inc.

A first of its kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer (NSCLC), under a collaboration agreement between Cancer Research UK and Asterias Biotherapeutics Inc.

 

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine